Paras Defence and Space Technologies Limited announced the approval of a grant of stock options to eligible employees under the Employee Stock Option Plan 2024. A total of 1,56,400 stock options have been granted in the second phase (Phase – 2) of the plan. The exercise price for these options is set at Rs. 650/- per share. The options carry a minimum vesting period of three years and an exercise window of five years post-vesting.
ESOP Grant Approval Details
The Nomination and Remuneration Committee of Paras Defence and Space Technologies Limited convened on March 13, 2026, to approve the grant of stock options to the company’s eligible employees under the newly established “Paras Defence and Space Technologies Limited – Employee Stock Option Plan 2024”.
Phase-2 Option Grant Summary
The specific details pertaining to this approval are summarized below:
| Particulars | Responses/Details |
|---|---|
| Scheme Name | Employee Stock Option Phase – 2 under “Paras Defence and Space Technologies Limited – Employee Stock Option Plan 2024” [Paras Defence ESOP 2024] |
| Options Granted (Phase 2) | 1,56,400 (One Lakh Fifty-Six Thousand Four Hundred) options, forming part of the total pool of 15,90,000 options. |
| Face Value per Share | Rs. 5/- each |
| Exercise Price | Rs. 650/- per share for eligible employees. |
| Vesting Period | Minimum 3 (three) years from the date of grant, in tranches. |
| Exercise Window | Maximum period of 5 (Five) years from the date of vesting. |
Context and Scheme Revisions
It is noted that the total option pool under the ESOP 2024 Scheme was previously revised from 7,95,000 to 15,90,000 options following a split/sub-division of equity shares on July 04, 2025, which reduced the face value from Rs. 10/- to Rs. 5/-.
This revision also impacted the earlier Phase – 1 grant (granted on January 22, 2025). The original grant of 78,450 options was adjusted to 1,56,900 options, and the exercise price was concurrently revised from Rs. 1,000/- to Rs. 500/- per option.
Current Status of Options
As of the announcement date, the options granted in this latest announcement (Phase – 2) are yet to be exercised, meaning there is no immediate impact on the company’s diluted earnings per share.
Source: BSE
